Amgen Elects Option On Cardiac Drug, Improving Cytokinetics' Strong Cash Position
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen’s decision to take exclusive license to CK-1827452 triggers a $50 million license fee to Cytokinetics.
You may also be interested in...
Double-Jointed Partnership With Servier Could Jumpstart Amgen’s CV Portfolio
Amgen gets U.S. rights to a pair of heart failure candidates from the French firm, with the lead candidate already approved in Europe and likely to be filed quickly at FDA. Meanwhile, Servier obtains EU commercialization rights to a CV drug partnered between Amgen and Cytokinetics.
Deals Of The Week Looks At How Amgen’s Global Expansion Affects Partnering
Plus perspectives on AstraZeneca/Pearl Therapeutics, Xenon/Isis, Questcor/Novartis, BMS/Simcere and more.
Cytokinetics R&D Day Spotlights Muscle Programs Beyond Heart Failure Drug
Cytokinetics skeletal troponin activator CK-‘357 generates buzz on the Street, even before proof-of-concept data is in.